AbbVie and Neurocrine Biosciences report positive Phase III trial results of Elagolix to treat endometriosis

AbbVie and Neurocrine Biosciences have reported positive results from two replicate pivotal Phase III clinical trials of Elagolix to treat premenopausal women suffering from endometriosis.

Source: Drug Development Technology - October 20, 2016 Category: Pharmaceuticals Source Type: news